Neuren Pharmaceuticals Limited (ASX:NEU) Reports DAYBUE Sales Growth and Upgrades Full-Year Income Guidance

Sonal Goyal

05 November 2026 03:56 PM AEDT

Neuren Pharmaceuticals Limited (ASX:NEU) Reports DAYBUE Sales Growth and Upgrades Full-Year Income Guidance

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Neuren Pharmaceuticals has upgraded its full-year 2026 guidance for total income from trofinetide, following materially improved Q3 2026 net sales of DAYBUE and the realisation of a milestone payment from the first commercial sale in Germany.
DAYBUE net sales in Q3 2026 grew significantly compared with the same period in 2025, driven by uptake of the DAYBUE STIX formulation among both existing and new patients in the United States.
The first commercial sale of DAYBUE in Germany during October 2026 triggered a milestone payment to Neuren under its licence agreement with Acadia Pharmaceuticals, marking the beginning of Neuren's Revenue participation from European sales.
Phase 3 study results for trofinetide in Rett syndrome in Japan were described as consistent with the earlier LAVENDER study, supporting a planned regulatory submission in 2027 and a potential launch in 2028, subject to regulatory approval.

Neuren Pharmaceuticals Limited (ASX:NEU) is an ASX-listed pharmaceutical company that develops drug therapies for serious neurological disorders. The company has granted an exclusive worldwide licence to Acadia Pharmaceuticals for the development and commercialisation of trofinetide, which is marketed as DAYBUE in oral solution form and DAYBUE STIX in powder form. DAYBUE is approved by the US Food and Drug Administration for the treatment of Rett syndrome in patients two years of age and older, and the oral solution has also received approval from regulatory bodies in the European Union, Canada, and Israel. Under the licence arrangement, Neuren receives tiered royalties on net sales and is entitled to milestone payments upon the achievement of specified commercial events. On 5 November 2026, Neuren reported Q3 2026 highlights and upgraded its full-year 2026 income guidance.

Q3 2026 Performance and Sales Momentum

DAYBUE net sales in Q3 2026 were meaningfully higher than the same quarter in the prior year, reflecting continued momentum in the US market. Growth in the period was attributed to two key drivers: healthy uptake of the DAYBUE STIX formulation among existing patients, and a continuing flow of new and restarting patients on therapy. The STIX formulation, which offers a powder-based alternative to the oral solution, had already been adopted by a majority of US DAYBUE users by the end of the quarter, a material increase from the proportion reported at the end of Q2 2026. A new US Patent covering weight-banded dosing of trofinetide was also allowed during Q3, extending patent protections for the DAYBUE Franchise by several years into the early 2040s.

Neuren's Royalty income for the quarter, earned on the basis of DAYBUE's net sales, also showed marked improvement compared with Q3 2025. The full-year 2026 royalty guidance for Neuren was revised upward to reflect the improved trajectory of global DAYBUE sales, as Acadia also upgraded its own full-year net sales guidance for the product. These revised guidance ranges incorporate continued growth in the US as well as the initial contribution expected from European markets following the Germany launch.

European Launch and Japan Development

The first commercial sale of DAYBUE in Germany during October 2026 represented a significant milestone for the trofinetide programme. This event triggered a milestone payment to Neuren under the terms of its licence agreement with Acadia for European rights. Under that agreement, Neuren is also entitled to tiered royalties on European net sales and further milestone payments upon the achievement of defined annual net sales thresholds across the European territory, which encompasses European Union member states as well as the United Kingdom, Iceland, Norway, Switzerland, and Liechtenstein. The initial patient treatment in Germany marks the beginning of Neuren's commercial participation in the European market, which represents a new and potentially growing revenue stream alongside the established US royalty base.

In Japan, Acadia has completed a Phase 3 study of trofinetide in Rett syndrome with results described as consistent with the earlier LAVENDER Phase 3 study that underpinned the original US approval. These results are supportive of a planned regulatory filing in Japan in 2027. A commercial launch in Japan remains subject to regulatory approval and is currently anticipated for 2028, should that approval be obtained. Acadia is also working to identify a distribution partner in preparation for the regulatory submission. For Neuren, a successful Japanese approval and launch would represent another addition to its global royalty-generating geography, adding to the US and European income streams.

Key Takeaways

Neuren Pharmaceuticals continues to benefit from the commercial progress of DAYBUE, with Q3 2026 net sales growth in the US demonstrating the ongoing adoption of trofinetide among Rett syndrome patients. The launch in Germany and the associated milestone payment mark the transition from a solely US-focused commercial profile to one with an emerging international dimension, with Japan presenting the next potential geographic expansion. The upgrade to full-year 2026 income guidance reflects the cumulative impact of the milestone payment and improving royalty expectations across global markets. Looking ahead, the Japan regulatory pathway and any further milestones or royalties from European sales growth are likely to be watched closely by investors tracking the value of Neuren's global licence arrangement with Acadia.

FAQs

Q: What is DAYBUE and what is it approved for?

A: DAYBUE (trofinetide) is a treatment for Rett syndrome, a rare genetic neurological disorder. It is available in oral solution form (DAYBUE) and powder form (DAYBUE STIX), and is approved by the US FDA for patients aged two years and older. The oral solution is also approved in the European Union, Canada, and Israel.

Q: What is the relationship between Neuren and Acadia Pharmaceuticals?

A: Neuren has granted Acadia Pharmaceuticals an exclusive worldwide licence to develop and commercialise trofinetide. Under this arrangement, Neuren receives tiered royalties on DAYBUE net sales and is entitled to milestone payments when specified commercial events are achieved, such as the first commercial sale in a new geography.

Q: Why was Neuren's income guidance upgraded?

A: The guidance upgrade reflects two key developments: an improvement in the full-year net sales trajectory for DAYBUE driven by DAYBUE STIX adoption and new patient growth in the US, and the realisation of a milestone payment earned upon the first commercial sale of DAYBUE in Germany in October 2026.

Q: What is the significance of the DAYBUE launch in Germany?

A: The German launch marks the first commercial sale of DAYBUE in Europe, triggering a milestone payment to Neuren. It also activates Neuren's entitlement to receive tiered royalties on European net sales, alongside potential further milestone payments as annual European sales reach defined thresholds.

Q: What is the status of trofinetide in Japan?

A: Acadia has completed a Phase 3 study of trofinetide in Japan with results consistent with the pivotal LAVENDER study. These results are supportive of a planned regulatory submission in 2027. A commercial launch in Japan is currently anticipated for 2028, subject to regulatory approval, and Acadia is working to identify a local distribution partner.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.